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INTRODUCTION
Today, clinical medicine possesses an extremely long list of different pharmaceutical
products and every year many new drugs are added to the list with the understanding
of molecular mechanisms of diseases. Scientists and physicians are never satisfied only
with a favorable drug action against the disease under treatment. The task of avoiding
undesirable drug actions on normal organs and tissues and minimizing side effects of
the therapy is very important. Thus, screening of biologically active compounds became
necessary, permitting the choice of drug with selective action on the appropriate organs
1
Acta Pharm. 55 (2005) 1–25 Review article
Liposomal drug delivery systems – Clinical applications
PARVEEN GOYAL1*
KUMUD GOYAL1





Lord Shiva College of Pharmacy
Near Civil Hospital, Post Box No. 63
Sirsa-125055, Haryana, India




University Institute of Pharmaceutical
Sciences, Punjab University
Chandigarh-160014, India
Received July 12, 2004
Accepted March 3, 2005
Liposomes have been widely investigated since 1970 as
drug carriers for improving the delivery of therapeutic
agents to specific sites in the body. As a result, numerous
improvements have been made, thus making this tech-
nology potentially useful for the treatment of certain dis-
eases in the clinics. The success of liposomes as drug car-
riers has been reflected in a number of liposome-based
formulations, which are commercially available or are
currently undergoing clinical trials. The current pharma-
ceutical preparations of liposome-based therapeutic sys-
tems mainly result from our understanding of lipid-drug
interactions and liposome disposition mechanisms. The
insight gained from clinical use of liposome drug delivery
systems can now be integrated to design liposomes that
can be targeted on tissues, cells or intracellular compart-
ments with or without expression of target recognition
molecules on liposome membranes. This review is mainly
focused on the diseases that have attracted most atten-
tion with respect to liposomal drug delivery and have
therefore yielded most progress, namely cancer, antibac-
terial and antifungal disorders. In addition, increased gene
transfer efficiencies could be obtained by appropriate se-
lection of the gene transfer vector and mode of delivery.
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or tissues. At the same time, many pharmacologically effective compounds cannot be
used as drugs due to their undesirable action on normal tissues. Their »specificity« for
the drug of choice, is not based on their ability to accumulate selectively in the target or-
gans. Normally, they are more or less evenly distributed in the whole body and to reach
the target zone the drug has to cross many other organs, cells, intracellular compart-
ments, etc., where it can be partially inactivated. To overcome this problem, a high con-
centration of drug has to be administered, which has a potential to cause undesirable
complications and is sometimes expensive too. The ideal solution to such problems is
the targeting of drugs using suitable carriers like serum proteins, immunoglobulins,
synthetic polymers, liposomes, niosomes, microspheres, erythrocytes, reverse micelles,
pharmacosomes, monoclonal antibodies, etc. (1, 2). Among these carriers, liposomes show
great potentials of effective delivery of drugs to the site of action and of controlling the
release of these drugs at a predetermined rate.
Liposomes are lyotropic liquid crystals composed of relatively biocompatible and
biodegradable materials and consist of an aqueous core entrapped by one or more bila-
yers of natural and/or synthetic lipids. Drugs with widely varying lipophilicities can be
encapsulated in liposomes either in the phospholipid bilayer, in the entrapped aqueous
core or at the bilayer interface. Reformulation of drugs in liposomes has provided an op-
portunity to enhance the therapeutic indices of various agents mainly through the alter-
ation of biodistribution. They are versatile drug carriers, which can be used to control re-
tention of entrapped drugs in the presence of biological fluids, controlled vesicle residence
in the systemic circulation or other compartments in the body and enhanced vesicle up-
take by target cells (3). Liposomes composed of natural lipids are biodegradable, biologi-
cally inert, weakly immunogenic (4), produce no antigenic or pyrogenic reactions and
possess limited intrinsic toxicity (5). Therefore, drugs encapsulated in liposomes are ex-
pected to be transported without rapid degradation and minimum side effects to the re-
cipients. Moreover, efforts have been made to assess the specificity of drug carriers to
the target organs, cells or compartments within the cells (1). Liposomes are better suited
for assessing their targetable properties because of the ease of modifying their surface
when compared to other drug carriers such as nanoparticles (6, 7) and microemulsions
(8, 9). Many approaches have been attempted to achieve targetable properties, including
noncovalent association of cell specific antibodies with liposomes (10), coating of lipo-
somes with heat aggregated immunoglobulins M (IgM) (11), covalent attachment of poly
and monoclonal antibodies to the liposomes (12–20), glycoprotein bearing liposomes
(21) and natural (22–24) and synthetic (25–29) glycolipid containing liposomes. The com-
pounds entrapped into the liposomes are protected from the action of external media,
particularly enzymes (30) and inhibitors. Moreover, liposomes afford a unique opportu-
nity to deliver the drugs into cells by fusion or endocytosis mechanism and practically
any drug can be entrapped into liposomes irrespective of its solubility.
CLINICAL APPLICATIONS
New drug delivery systems such as liposomes are developed when an existing for-
mulation is not satisfactory and reformulation in liposomes offers clear benefits with re-
spect to targetability, therapeutic efficacy and safety compared to the existing formula-
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tions. Lack of specificity in pharmacologically active agents is an obstacle to their effective
use in biological research and medicine. It follows that any approach enabling an agent
to reach its target selectively and in a controlled fashion would contribute to the elimina-
tion of problems inherent in conventional methods. One such approach was the devel-
opment of a non-toxic and biodegradable carrier capable of containing a variety of sub-
stances of biological interest that the carrier could, upon contact with the leaving entity,
direct to the site of action and subsequently allow to perform their task. It has been well
established that liposomes can meet many of these requirements, i.e., liposome formula-
tions of some drugs have shown a significant increase in therapeutic efficacy and/or
therapeutic indices in preclinical models and in humans compared to conventional for-
mulations. Encouraging results of liposomal drugs in the treatment or prevention of a
wide spectrum of diseases in experimental animals and in human, indicate that more
liposome-based products for clinical and veternary applications may be forthcoming
(31). These could include treatment of skin and eye diseases, antimicrobial and antican-
cer therapy, metal chelation, enzyme and hormone replacement therapy, vaccine and di-
agnostic imaging, etc. Below, we discuss some of the liposome applications with realistic
prospects of being developed for clinical use.
Cancer therapy
Cytotoxic drugs can distribute non-specifically throughout the body, lead to death
of normal as well as malignant cells, thereby giving rise to a variety of toxic side effects.
Entrapment of these drugs into liposomes resulted in increased circulation lifetime, en-
hanced deposition in the infected tissues, protection from the drug metabolic degrada-
tion, altered tissue distribution of the drug, with its enhanced uptake in organs rich in
mononuclear phagocytic cells (liver, spleen and bone marrow) and decreased uptake in
the kidney, myocardium and brain. To target tumors, liposomes must be capable of leav-
ing the blood and accessing the tumor. However, because of their size liposomes cannot
normally undergo transcapillary passage. In spite of this, various studies have demon-
strated accumulation of liposomes in certain tumors in a higher concentration than found
in normal tissues (32, 33). One or more of the following factors may account for this: (i)
higher endocytic activity of some tumor cells combined with augmented local perme-
ability of capillaries allowing the passage of small liposomes, a phenomenon also de-
scribed as »the enhanced permeability and retention effect« which can facilitate liposo-
me uptake, (ii) diffusion of drugs from liposomes either during circulation or after they
have been lodged in tissues adjacent to tumors, followed by preferential drug entry into
the tumor mass, (iii) liposomes may be phagocytosed by circulation monocytes, which
subsequently migrate to tumors, (iv) sustained release effect of liposomes may enhance
the drugs cytotoxic effect. Passive targeting of long circulating liposomes to tumor tis-
sues may be useful for delivering cancer chemotherapeutic agents to the target tumors,
since there is a positive correlation between the circulation time of liposomes and their
localization in tumors.
Many research efforts have been directed towards improving the safety profile of
the anthracycline cytotoxics, doxorubicin (DXR) and daunorubicin (DNR), along with
vincristine (VCR), which are associated with severe cardiotoxic side effects, although
acute gastrointestinal effects and other toxicities may also occur. Liposomal entrapment
of these drugs showed reduced cardiotoxicity, dermal toxicity and better survival of ex-
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perimental animals compared to the controls receiving free drugs (32). Such beneficial
effects of liposomal anthracyclines have been observed with a variety of liposomal for-
mulations regardless of their lipid composition provided that lipids used high choles-
terol (Cho) concentration or phospholipids with high phase transition temperature (Tc)
are conducive to drug retention by the vesicles in the systemic circulation (34).
DXR is a potent antineoplastic agent active against a wide range of human cancer
including lymphomas, leukemia and solid tumors. However, administration of this drug
produces acute toxicity in the form of bone marrow depression, alopecia and oral ulcer-
ation (35–37). DXR entrapped in liposomes shows reduced non-specific toxicity and ma-
intains or enhances anticancer effect. DXR hydrochloride constitutes the first liposomal
product (DoxilTM) to be licensed in the United States. Surface grafted methoxypolyethylene
glycol (MPEG) provides the hydrophilic »stealth« coating, which allows the DoxilTM
liposomes to circulate in the blood stream for prolonged periods. The lipid matrix and
an internal buffer system combine to keep virtually all the DXR encapsulated during
liposome residence in the circulation. This means that the drug is not free to exert its
toxic effects (38, 39). Liposome association alters the drug pharmacokinetics and thus
the liposome has a half-life of approximately 55 hours in humans, whereas the free drug
distributes to the tissues within a few minutes and is entirely cleared from circulation
within 24 hours (40). Liposomal formulation showed decreased toxic effects of DXR; a
dose higher than the LD50 could be administered without acute toxicity, which suggests
that these liposomes extravasate from the endothelium of tumor tissues and reside around
tumor cells where they release the drug into the interstitial fluid. Therefore, the thera-
peutic effect was achieved by a slow and sustained release of the drug at the target site.
Furthermore, liposomal DXR has substantial activity against ovarian cancer in patients
that failed to respond to platinum and paclitaxel-based regimens. The responses achi-
eved with liposomal DXR were durable and maintained with minimal toxicity (41). En-
capsulation of DXR in stealth liposomes showed significant accumulation, enhanced
therapeutic efficacy and reduced toxic effect against human pancreatic carcinoma AsPC-1,
implanted into nude Swiss mice compared to DXR suspension. Increased penetration
into the tumor and a long presence with a slow drug release from liposomes in the tu-
mor account for the enhanced therapeutic effects (42).
A new lipid formulation containing DXR that has been optimized for both mild hy-
perthermic temperatures and rapid drug release times has been developed (43). This new
liposome formulation, in combination with mild hyperthermia, was found to be signifi-
cantly more effective than the free drug or current liposome formulations for reducing
tumor growth in a human squamous cell carcinoma xenograft line. Ishida et al. (44) de-
veloped pH-sensitive liposomes, targeted at the CD19 epitope on B-lymphoma cells,
which showed enhanced DXR delivery into the nuclei of the target cells and increased
cytotoxicity compared to non-pH-sensitive liposomes. This suggested that the targeted
pH-sensitive formulations of drugs might be able to increase the therapeutic efficacy of
entrapped drugs. Moreover, a unique liposomal formulation of DXR (TLC D-99) is active
against AIDS (acquired immunodeficiency syndrome) related Kaposi’s sarcoma and re-
sulted in improved safety and efficacy profile, and the response is dose-dependent (45).
Ten Hagen et al. (46) reported that systemic administration of low-dose tumor ne-
crosis factor-alpha (TNF-alpha) augments the antitumor activity of a liposomal formula-
tion of DXR. Addition of TNF-alpha to the DXR liposomes regimen, which by itself in-
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duced some tumor growth delay, resulted in massive necrosis and regression of tumors.
Furthermore, a significant increase of the liposomal drug in tumor tissue was observed
when TNF-alpha was co-administered. The antitumor effects against solid tumors, such
as Meth A sarcoma, MH-134 hepatoma and colon 26 adenocarcinoma, were examined
after intratumoral administration of liposomes and TNF solution. The antitumor effects
of liposomes against solid tumors were superior to those of TNF solution. In particular,
the antitumor effect of positively charged liposomes was superior to that of negatively
charged liposomes and TNF solution. Further, positively charged liposomes containing
a higher dose of TNF than the solution could be administered without killing the mice
because of reduced side effects (47).
The ability to selectively target liposomal anticancer drugs via specific ligands against
antigens expressed on malignant cells could improve the therapeutic effectiveness of
liposomal preparations as well as reduce the adverse side effects associated with chemo-
therapy. Immunoliposomes conjugated with S5A8 monoclonal antibody, an anti-idiotype
antibody to 38C13 murine B-cell lymphoma, when loaded with DXR exhibited a long
circulation time and showed more effectiveness for prolonging the survival of mice be-
aring 38C13 tumor than non-targeted liposomal DXR or free DXR plus empty immuno-
liposomes (48). Lopes de Menezes et al. (49) reported that targeted monoclonal antibody,
anti-CD19, liposomes containing DXR may be selectively cytotoxic to malignant B cells
expressing CD19 surface antigens, compared to DXR entrapped in nontargeted stealth
liposomes/free DXR, and may be useful for selective elimination of circulating malig-
nant B cells in vivo. Neuroblastoma (NB) tumor, but not normal tissues, overexpresses
the disialoganglioside GD (2) at the cell surface. Anti-GD (2) whole antibodies aGD (2)
or their corresponding Fab’ fragments were covalently coupled to stealth immunolipo-
somes (aGD (2)-SIL or Fab’-SIL) containing DXR and showed higher cytotoxicities than
untargeted liposomes. DXR loaded Fab’-SIL also showed specific binding, uptake, and
cytotoxic effects on several GD (2)-positive NB cells in vitro. Fab’-SIL encapsulated DXR
formulations led to total inhibition of metastatic growth of human NB in a nude mouse
metastatic model (50). Furthermore, long-term survivors were obtained when treated
with Fab’-SIL encapsulated DXR but not among untreated mice and those treated with
free anti-GD (2) Fab’ fragments or free-DXR. Fab’-SIL containing DXR also prevented
the establishment and metastatic growth of tumor cells in different organs (51).
A new type of long-circulating immunoliposomes, i.e., polyethyleneglycol (PEG)
immunoliposome attached antibodies at the distal end of PEG chain, the so called pen-
dant type immunoliposomes, showed much higher targetability than the ordinary im-
munoliposomes on both targeting sites of lung endothelial cells and solid tumor tissue.
This is due to the free PEG chains (not linked to the antibody) effectively avoiding the
reticuloendothelial systems (RES) uptake of liposomes, resulting in elevated blood con-
centration and enhanced target binding of immunoliposomes. The presence of free PEG
does not interfere with the binding of the terminally linked antibody to the antigen. For
targeting on the vascular endothelial surface in the lungs, 34A antibody, which is highly
specific to mouse pulmonary endothelial cells, was conjugated to make the pendant
type immunoliposomes (34A-PEG-ILP). 34A-PFG-ILP showed a significantly higher tar-
geting degree than the ordinary type of immunoliposomes (19, 20, 52). For targeting on
the solid tumor tissue, the Fab’ fragment of 21B2 antibody and transferrin pendant type
immunoliposomes (Fab’-PFG-ILP and TF-PEG-ILP) were used, which showed a low
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RES uptake and a long circulation time, and resulted in enhanced accumulation of the
liposomes in the solid tumor. TF-PEG-ILP was internalized into tumor cells with recep-
tor-mediated endocytosis after extravasation into tumor tissue. The pendant type immu-
noliposomes can escape from the gaps between adjacent endothelial cells and openings
at the vessel termini during tumor angiogenesis by passive convective transport much
higher than ligand directed targeting. Active targeting on tumor tissue with the pendant
type immunoliposomes is particularly important for many highly toxic anticancer drugs
in cancer chemotherapy. The ultimate goal of pendant type immunoliposome is the in-
corporation of a fusogenic molecule, which would induce liposome fusion following
their binding to the target cells or their internalization by endocytosis (52).
DXR also plays an important role in the treatment of breast cancer, both in the
adjuvant and metastatic settings. However, the benefits of conventional DXR in terms of
antitumor activity are limited by its therapeutic index. Pegylated liposomal DXR pro-
vides tumor-targeted efficacy without many of the toxicities associated with conven-
tional DXR, including myelosuppression, alopecia, nausea and vomiting, and most im-
portantly, cardiac toxicity. It has also demonstrated efficacy in combination with other
agents or modalities, including cyclophosphamide, paclitaxel, docetaxel, gemcitabine,
vinorelbine, and hyperthermia. Owing to its comparable efficacy and favorable safety
profile, pegylated liposomal DXR may be a useful alternative to conventional DXR, as
well as other agents commonly used in the treatment of breast cancer (53, 54). Sterically
stabilized liposomes derived from the antitumor agent hexadecyl phosphocholine showed
reduced uptake by the mononuclear phagocyte system (MPS) and improved antitumor
activity in breast carcinoma in nude mice compared to conventional hexadecyl phos-
phocholine liposomes or free hexadecyl phosphocholine (55). Cisplatin when encapsu-
lated in polyethyleneglycol-coated long-circulating liposomes results in prolonged cir-
culation time and enhanced tumor uptake in different mouse tumor models. In spite of
these results, due to the extremely slow release rate, no superior antitumor activity is
seen for liposomal cisplatin over plain cisplatin. Results demonstrated that improve-
ment in release kinetics of the prepared liposomes would lead to higher therapeutic effi-
cacy of entrapped cisplatin (56).
Preclinical and clinical investigations have demonstrated significantly increased ef-
ficacy and decreased toxicity of liposomes containing DNR (DaunoXomeTM) in comparison
with free DNR (57) in the treatment of acute leukemia (58). However, in the treatment of
hepatocellular carcinoma and liver cirrhosis liposomal DNR showed mild haematologi-
cal toxicities and significant hepatic toxicity, which warns against further assessment of
these liposomes in patients with hepatocellular carcinoma and liver cirrhosis (59). How-
ever, liposomal DNR showed encouraging results in the treatment of advanced cutane-
ous T-cell lymphoma (60). Furthermore, liposomal DNR and carboplatin plus etoposide,
used to treat children with recurrent high-grade glioma after surgery and with progres-
sive teratoid/rhabdoid tumor, showed encouraging results with only little and transient
hematological toxicity (61). Liposomal encapsulation of VCR resulted in increased and
prolonged plasma concentration, which is associated with increased antitumor activity
(murine P388 ascitic tumor) but not increased drug toxicities compared to the unencap-
sulated drug (62). Guthlein et al. (63) found that VCR entrapped into a vesicular phos-
pholipid gel consisting of densely packed liposomes was an effective delivery system
with superior antitumor activity compared to conventional VCR against human small
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cell lung carcinoma LXFS 650 and the human mammary carcinoma MX1. Sustained re-
lease and passive tumor targeting can explain the enhanced efficacy.
Administration of magnetic adriamycin (ADR) liposomes under magnetic force us-
ing a permanent magnet (0.4 Tesla) implanted in solid tumor produced an approxima-
tely 4-fold higher ADR concentration in the tumor than free ADR solution. Liposomal
formulation resulted in an increased ADR concentration in the liver and lungs and a de-
creased concentration in the heart. The results indicated that intravenously administered
magnetic ADR liposomes can be used to effectively deliver ADR to osteosarcoma, Os515,
implanted with a magnet, as well as to the lungs, a common site of osteosarcoma metas-
tases (64). Furthermore, it is possible to achieve complete regression of osteosarcoma in
hamster following injection of magnetite cationic liposomes in osteosarcoma and genera-
tion of hyperthermia by an alternating magnetic field (65). The antitumor effect of mel-
phalan encapsulated in thermosensitive small unilamellar vesicles administered in com-
bination with hyperthermia was studied in C57B1/6 mice bearing B16F10 melanoma. It
was found that in vivo efficacy of liposome-encapsulated melphalan in combination with
hyperthermia was higher than that of an equivalent concentration of free melphalan with
or without heating. These results suggested that the combination of drug-loaded natural
lipid-derived thermosensitive liposomes with local hyperthermia at the tumor site could
be useful in enhancing drug delivery to tumors and improving its therapeutic efficacy in
the treatment of solid tumors (66). Furthermore, animals receiving multimodality therapy
involving irradiation followed by injection of thermosensitive liposomal melphalan and
hyperthermic treatment of the tumor-bearing leg at 42  0.5 C for 1 hour showed marked
tumor regression compared to untreated controls or animals treated with a combination
of radiation and hyperthermia or radiation and free-drug melphalan. The study showed
more extensive tumor cell killing, tumor growth delay and prolonged survival produced
by a combination of radiation, thermosensitive-liposome-entrapped melphalan and hy-
perthermia compared to animals receiving single-modality or bimodality treatments (67).
Overexpression of lectins by malignant cells was applied for in vitro targeting of lipo-
somes equipped with a saccharide vector and loaded with a lipid derivative of the anti-
cancer agent sarcolysine. It was shown that active saccharide ligands increased the level
of the vectored liposome binding to malignant cells by 50–80% as compared to liposomes
without vector. Targeted drug-loaded liposomes had the cytotoxic activity much higher
than the vector-free ones (68). When given by intravenous route, mannobiose mono ara-
chidic acid esters (MAE) modified liposomes were eliminated from the systemic circula-
tion more rapidly than control liposomes without modification. Whilst the modification
did not affect the distribution of liposomes to the kidney, lungs, or thymus, it increased
the distribution to liver and spleen. The uptake in the hepatic parenchymal cell fraction
was not influenced by MAE incorporation. Taking into account the fact that endothelial
cells do not take up particles larger than 100 nm, the increase in the distribution to liver
was ascribed to an increase in the uptake by Kupffer's. These results suggest that man-
nobiose mono fatty acid esters are useful in the targeting of liposomes on Kupffer's and
other macrophages and thereby can be a useful tool for treating tumors of these cells
(69). Another application in tumor therapy includes liposome entrapped mitoxantrone
(LEM) of significantly decreased toxicity, which showed altered pharmacokinetics and
enhanced efficacy. This suggests that LEM may provide a viable alternative to the clini-
cal use of conventional mitoxantrone against the human hormone-independent prostate
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carcinoma (70). A monoclonal antibody against the rat colon carcinoma CC531 was co-
valently coupled to liposomes containing a dipalmitoylated derivative of the anti-cancer
drug 5-fluoro-2’-deoxyuridine (FUdR-dP), as a prodrug, in their bilayers. The parent drug
was released intracellularly and showed a much stronger inhibition of CC531 cell growth
in vitro than in non-targeted liposomes (18).
Etoposide exerts its antineoplastic effect by forming a ternary complex with topo-
-isomerase II and deoxyribonucleic acid (DNA), leading to DNA breaks and cell death.
However, it causes myelosuppression and its lipophilicity poses a major limitation dur-
ing administration. Encapsulation of etoposide in liposomes significantly delayed tumor
growth compared to non-liposomal etoposide. The maximum tolerated dose was signifi-
cantly higher in the group treated with liposomal etoposide, which also exhibited a les-
ser degree of myelosuppression than the animals treated with non-liposomal etoposide
(71). Sudimack et al. (72) designed pH-sensitive liposomes that showed excellent stability
at pH 7.4 and underwent rapid destabilization upon acidification. These novel liposomes
were evaluated for intracellular delivery of entrapped cytosine-beta-D-arabinofuranoside
(araC) in human oral cancer cells with elevated folate receptor (FR) expression. The FR,
which is amplified in many types of human tumors, has been shown to mediate the in-
ternalization of folate-derivatized liposomes into an acidic intracellular compartment.
FR-targeted oleyl alcohol-based pH-sensitive liposomes showed approximately 17-times
higher FR-dependent cytotoxicity in cancer cells compared to araC delivered via FR-tar-
geted non-pH-sensitive liposomes. This data indicates that pH-sensitive liposomes based
on oleyl alcohol combined with FR-mediated targeting are promising delivery vehicles
for membrane impermeable therapeutic agents.
A new boron cholesterol-carborane conjugate (BCH) has been synthesized as a po-
tential targeting agent for boron neutron capture therapy (BNCT) of cancers. BCH en-
capsulated in liposomes delivered sufficient levels of boron to 9L rat glioma cells in vitro,
indicating that BCH is a promising approach for BNCT. However, the uptake appeared
to depend upon BCH concentration in the media as well as on the confluence of cells.
Higher boron uptake by nonconfluent cells indicated that active growth of cells was a
factor in the uptake of this compound (73). Liposomes containing high levels of exoge-
nous natural ceramide lipid in the bilayer delivered the ceramide at a controlled rate
and showed antitumor activity in vivo against the J774 ascites tumor model. Shabbits
and Mayer (74) demonstrated the potential utility of ceramide-based liposomes as a no-
vel strategy for cancer chemotherapy based on controlled ceramide delivery. Ozpolat et
al. (75) suggest that intravenous administration of liposomal all-trans-retinoic acid (L-ATRA)
maintains higher and stable plasma ATRA concentrations than oral ATRA in healthy
subjects after repetitive administration. L-ATRA with a favorable pharmacokinetic pro-
file may have potential advantages over oral ATRA and may be more efficacious in the
treatment of acute promyelocytic leukemia or other retinoid-responsive cancers.
Encapsulation of c-myb antisense oligodeoxynucleotides into immunoliposomes
appears to enhance their toxicity toward targeted cells while shielding non-targeted cells
from antisense effects and may be efficacious for the delivery of drugs with broad thera-
peutic applications to tumor cells (76). Moreover, coupling of an anti-CD19 targeted an-
tibody with charge neutralized liposome-antisense oligodeoxynucleotides (asODN) was
effective in delivering an asODN to a multidrug-resistant human B-lymphoma cell line
in vitro, decreasing the activity of P-glycoprotein. No such activity was observed for
non-targeted liposomes and free asODN (77, 78).
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Photodynamic therapy (PDT) as a cancer treatment is notable for its quite low side
effects in comparison with those of chemotherapy and radiotherapy. However, the accu-
mulation of porphyrin derivatives used in PDT in tumor tissues is rather low. Therefore,
the benzoporphyrin derivative monoacid ring A (BPD-MA) was encapsulated in long
circulating liposomes to enhance targeting on tumors. Tumor regression in mice bearing
Meth A sarcoma and complete tumor curing were observed when these liposomes were
injected and laser-irradiated, as compared to BPD-MA solution or BPD-MA entrapped in
conventional liposomes. These results suggest that a long-circulating liposomal formula-
tion of photosensitive agents is useful for PDT (79). Enhanced in vitro cytotoxic activity
against leukaemic cells was found for combinations of the ether lipids, octadecyl phos-
phocholine and ET-18-OCH3, with both teniposide and paclitaxel. The benefit of the
liposomal formulation form for ether lipids was supported by the fact that their hae-
molytic activity was much reduced when they were incorporated into liposomes (80).
Antimicrobial therapy
Treatment of mycobacterial infections differs from that of other bacterial diseases
because of several properties possessed by the mycobacteria and the host. A hallmark of
mycobacteria is the complex lipid-rich cell envelope that protects the organism from both
the host response and antimycobacterial therapy. In addition, mycobacteria are faculta-
tive intracellular parasites, which generally cause a more chronic type of disease. These
properties put greater constraints on efficient therapy. To be effective, drugs must be
able to penetrate the host macrophage, infected intracellular sites and preferably have
reduced toxicity and be effective at low doses to allow prolonged therapy (32, 81).
Antibiotics can only act against intracellular infections if they can penetrate the
phagocytic cells. It is a well known fact that liposomes are able to localize in the liver
and spleen, especially the RES component, where many pathogenic microorganisms re-
side; they can be therefore used for targeting of antibiotics on these organs. In a simple
in vitro culture, liposomal neomycin (82) and penicillin (83) were found to be active
against bacteria, whereas liposome entrapment markedly reduced the antimicrobial ac-
tivity of chloramphenicol (84). Liposome encapsulation alters the tissue distribution of
gentamicin when given by intravenous route to rabbits (85); however, when adminis-
tered by intramuscular route, it resulted in sustained release from the injection site, pro-
viding prolonged plasma concentrations of the drug (86). Moreover, Lutwyche et al. (87)
demonstrated that encapsulation of membrane-impermeative antibiotics such as genta-
micin in appropriately designed lipid-based delivery systems can enable their use in tre-
ating intracellular infections.
Incorporation of rifabutin in liposomes resulted in a significant enhancement of ac-
tivity against Mycobacterium avium infection compared to free rifabutin (88). Moreover,
the antitubercular activity of rifampin was considerably increased when encapsulated in
egg phosphatidylcholine liposomes. A further increase in the activity was observed when
the macrophage activator tetrapeptide tuftsin was grafted on the surface of drug-loaded
liposomes. Rifampin delivered twice weekly for two weeks in tuftsin-bearing liposomes
was at least 2,000 times more effective than the free drug in lowering the load of lung
bacilli in infected animals (89). Liposome encapsulated clarithromycin may be more ef-
fective than the free form against Mycobacterium avium intracellular (MAI) infections in
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vivo, and the use of a combination therapy with ethambutol could further enhance the
efficacy (90). Furthermore, when the activity of TLC G-65 (liposomal gentamicin prepa-
ration), alone and in combination with rifapentine, clarithromycin, clofazimine and eth-
ambutol, was evaluated in the beige mouse model of disseminated Mycobacterium avium
infection showed that the combination of rifapentine and TLC G-65 was more active
than either agent alone. The activity of clarithromycin in combination with TLC G-65
was similar to that of either agent alone. Clofazimine improved the activity of TLC G-65
with respect to the spleen, while ethambutol improved the activity with respect to the
liver (91). Entrapment of ciprofloxacin in liposomes increases the circulation half-life of
the drug when given by intravenous route in mice, which is associated with enhanced
delivery of the drug to the liver, spleen, kidneys, and lungs. Furthermore, liposomal en-
trapment was associated with increased therapeutic efficacy against the Salmonella typhi-
murium infection model in mice (92). Stevenson and coworkers (93) showed enhanced
activity of streptomycin and chloramphenicol against Escherichia coli in the cells of the
J774 murine macrophage line mediated by liposome delivery. The apparent intracellular
antibacterial activity of antibiotics was increased more than tenfold by entrapment in
liposomes. Khalil et al. (94) demonstrated a higher accumulation of streptomycin sulfate
in the liver and spleen when encapsulated in liposomes than that exhibited by the free
drug. Furthermore, streptomycin liposomes, when administered in two intravenous in-
jections, caused greater reduction of the colony forming unit in the spleen, lungs and
liver, when compared with the free drug, which was given in a much higher dose by in-
tramuscular route (95). Moreover, long circulating liposomes and conventional liposo-
mes encapsulating streptomycin, when given twice weekly, showed bactericidal activity
against Mycobacterium avium complex (MAC) strain 101 in the spleen when the level of
infection after treatment was compared to that before treatment (96).
The current treatment of immuno-compromised patients (AIDS patients) infected
with MAC microorganisms is ineffective, probably because the organism resides intra-
cellularly, mostly in monocytes. The rationale for liposome encapsulation of aminogly-
cosides is the possibility to increase the therapeutic index of this class of antibiotics by
increasing aminoglycosides concentration at the site of infection and/or by reducing the
toxicity of these drugs (97). To this end, effective treatment of MAC in mice was achi-
eved with liposomal amikacin (98). Furthermore, amikacin in small, low-clearance lipo-
somes (MiKasomeTM) has prolonged plasma and tissue residence and in vivo activity
against extracellular infections, including Klebsiella pneumoniae and Pseudomonas endocar-
ditis (99). Further, encouraging results were previously obtained with liposomal ampi-
cillin in the treatment of Listeria monocytogenes (100), liposomal cefalothin against Salmo-
nella typhimurium (101), liposomal benzyl penicillin in Staphylococcus aureus infection in
mice (102) and with liposomal dihydrostreptomycin against intracellular Staphylococcus
aureus (103). The efficacy of liposome-encapsulated ciprofloxacin or azithromycin in the
therapy of intracellular Mycobacterium avium infection showed increased cellular deliv-
ery of these antibiotics and suggested that efficiency of intracellular targeting was suffi-
cient to mediate enhanced antimycobacterial effects (104).
Another group of microbial diseases, severe disseminated fungal infections, has be-
nefited substantially from the use of liposomes as drug delivery system. Polyene antibi-
otics such as amphotericin B (AmB) and nystatin are useful in systemic fungal infections
such as candidosis and aspergillosis. The mechanism of AmB action involves intercala-
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tion of the drug molecules into fungal cell membranes. Several molecules associate within
the membrane, forming a barrel pore through which cell constituents are lost; this leads
to metabolic disruption, osmotic imbalance and cell death. AmB selectivity of action is
due to its higher affinity for the ergosterol of fungal membranes, although it binds with
cholesterol as well (105).
The conventional amphotericin B (CAB) therapy, fungizone, a mixed colloidal dis-
persion of AmB with deoxycholate as surfactant, is associated with toxicity problems,
since some binding of AmB to mammalian cells is inevitable (106). The most serious ad-
verse effect of CAB therapy is nephrotoxicity, although clinical efficacy is also limited by
a high incidence of haematological adverse effects (107). Data from both animal and hu-
man studies clearly indicate that both renal and hematological toxicity with the liposo-
mal formulations of AmB are significantly reduced comparied to CAB (108, 109).
Three liposomal and lipid-based formulations of AmB have been commercially in-
troduced; they are capable of attenuating the toxicity of AmB, i.e., lipid-based AmB pre-
parations, AmB lipid complex (ABLC, Abelcet), AmB colloidal dispersion (ABCD, Am-
photec or Amphocil), and liposomal AmB (AmBisome). These formulations have
shown that antifungal activity is maintained while toxicity is reduced (110). Abelcet
and Amphocil, which do not even possess the conventional concentric phospholipid
bilayer structure, provide examples of liposomal/lipid-carrier versatility. In animal mo-
dels, AmBisome is effective in treating both intracellular (leishmaniasis and histoplas-
mosis) and extracellular (candidosis and aspergillosis) systemic infections. Because of its
low toxicity at the organ level, intravenous AmBisome can be safely delivered in a
markedly high dose for the treatment of systemic fungal infections. AmBisome appears
to localize at sites of infection in the brain (cryptococcosis, aspergillosis, coccidioidomy-
cosis), lungs (blastomycosis, paracoccidioidomycosis, aspergillosis) and kidneys (candi-
dosis) in animal models, delivering AmB, which remains bioavailable in tissues for sev-
eral weeks following treatment (111). Multicentre studies with AmBisome have shown
that augmented concentration of the drug in the blood and tissues of mice and rats
could be achieved with non-toxic doses (112). Using the same formulation, Adler-Moore
et al. (113) were able to show, in preclinical trials, superior efficacy of AmBisome against
murine candidosis and cryptococcosis as compared to CAB. A large number of clinical
trials have confirmed the effectiveness of AmBisome as a safe alternative to CAB in the
majority of patients with invasive or superficial fungal infections (114–116). Moreover, in
patients with moderate to severe histoplasmosis associated with AIDS, liposomal AmB
was found to be a less toxic alternative to AmB and was associated with improved sur-
vival (117). AmBisome has shown a significant reduction in fungal colonization and in-
vasive Candida infections compared to placebo in a prospective, double blind study in
bone marrow transplantation, and eradication of invasive fungal infections in children
undergoing bone marrow transplantation (118). Compared to AmBisome, another lipo-
somal formulation of AmB (L-AMP-LRC-1) was found to be more effective at a lower
dose in neonatal candidiasis (119).
A number of factors appear to be responsible for the improved safety profile achiev-
ed with these three lipid-based commercial preparations of AmB (120). The drug is asso-
ciated with the lipid carrier, and is therefore unavailable to interact with mammalian cells
and to exert its toxic effects. The carriers remain stable in the circulation and no uncon-
trolled drug leakage from the carriers occurs. The drug pharmacokinetic profile is also
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altered, which plays an integral role in reducing drug toxicity (120). Association with
lipid carriers facilitates the uptake of the system by the MPS organs of the liver and sple-
en, the main sites of systemic fungal infections. Engulfment of liposomes by circulating
monocytes, and the migration of the latter to sites of infection, represents a further me-
chanism of increasing AmB concentration at the sites of infections.
The improved antifungal therapy with liposomal AmB resulted in incorporation of
nystatin into liposomes (19, 121, 122). Liposomal nystatin formulation is under develop-
ment and the studies have provided encouraging data. Furthermore, lipid-based formu-
lations of hamycin, miconazole, and ketoconazole have been developed but remain ex-
perimental (110). Besides their antifungal use, liposomal polyene antibiotics are expected
to disrupt HIV (human immunodeficiency virus) since the lipid envelope of HIV has a
higher cholesterol concentration than most normal human cells (123). In vitro screening
indicated that liposomal nystatin is effective to suppress the expression of HIV at con-
centrations that are not toxic to uninfected cells (124).
Using the mannosyl-fucosyl receptors on macrophages, mannosylated liposomes
loaded with an indigenous drug, andrographolide, were made to target this antileish-
manial drug to treat experimental leishmaniasis in the hamster model. These liposomes
were found to be most potent in reducing the parasitic burden in the spleen as well as in
reducing hepatic and renal toxicity (125). Similarly, the efficacy of freeze-dried empty
liposomes encapsulated with an antimonial drug, meglumine antimoniate, was evalu-
ated in hamsters experimentally infected with Leishmania chagasi. A significant reduction
of liver parasite burdens was observed in animals treated with these liposomes compar-
ed to control animals treated with free meglumine antimoniate. This novel liposome-ba-
sed meglumine antimoniate formulation appears to be promising as a pharmaceutical
product for the treatment of visceral leishmaniasis (126). When DXR was targeted on
macrophages infected by Leishmania donovani, by incorporating it in immunoliposomes
prepared by grafting Fab’(2) of anti-51-kDa antibody onto the liposomal surface, it showed
complete elimination of the spleen parasite burden in mice compared to 45% and 84%
parasite suppressive effects with similar doses of free and liposomal drugs (doxosome),
respectively. Furthermore, immunodoxosome and doxosome were generally less toxic
than the free drug in the treatment of visceral leishmaniasis (127).
Gene therapy
A number of systemic diseases are caused by lack of enzymes, factors due to miss-
ing or defective genes. Gene delivery systems are designed to control the location of ad-
ministered therapeutic genes within the patient’s body. Successful in vivo gene transfer
may require: (i) condensation of the plasmid and its protection from nuclease degrada-
tion, (ii) cellular interaction and internalization of condensed plasmid, (iii) escape of the
plasmid from endosomes (if endocytosis is involved), and (iv) plasmid entry into cell
nuclei (128). Gene therapy methods involve introduction of genetic material into the pa-
tient’s cells to synthesize the therapeutic protein. Direct administration of genes to pa-
tients may be virally or non-virally mediated. As viruses represent a highly suitable vector
for gene transfer, several viruses including retrovirus, adenovirus, adeno-associated-virus
and herpes virus have been investigated for their potentials in gene delivery. However,
there is always the potential risk that the viruses woned become replication competent
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and therefore infectious, immune and inflammatory responses have also been reported
in clinical trials. In recent years, several attempts have been made to restore the gene ex-
pression by delivery of relevant exogenous DNA or genes to cells (129).
The drawbacks associated with the use of viral vectors, namely those related to
safety problems, have prompted investigators to develop alternative methods of gene
delivery, cationic lipid-based systems being the most representative ones. Plasmid lipo-
some complexes have many advantages as gene transfer vehicles over viral based vec-
tors (129): (i) these complexes are relatively nonimmunogenic because they lack prote-
ins, (ii) liposomes or lipid complexes can be used for transfection of large-sized genetic
material, and (iii) viruses, unlike plasmid liposome complexes, may replicate and cause
infection. Despite extensive research in the last decade on the use of cationic liposomes
as gene transfer vectors and the development of elegant strategies to enhance their bio-
logical activity, these systems are still far from being viable alternatives to the use of vi-
ral vectors in gene therapy (130).
Cationic liposomes are considered to be a potential non-viral human gene delivery
system (131–137). These liposomes are usually composed of cationic lipid derivatives
and a neutral phospholipid such as dioleoylphosphatidyl ethanolamine (DOPE). Widely
accepted cationic liposome formulations are lipofectin, lipofectamine, transfectace, trans-
fectam and DC-Cho 3BN-(N,N-dimethylaminoethane) carbamoyl-cholesterol. Cationic
liposomes based on dioleyloxypropyl trimethylammonium chloride (DOTMA), such as
lipofectin, and several other types have demonstrated success both in in vitro and in vivo
gene delivery (138, 139). The negatively charged genetic material, for example, plasmid,
is not encapsulated in liposomes but complexed with cationic lipids by electrostatic in-
teractions. Plasmid liposome complexes are thought to enter the cells through fusion
with the plasma or endosome membrane (140). These liposomes were generally more ef-
fective in transfecting genes than micelles of the same lipid composition, thus suggesting
a role for the bilayer structure in facilitating transfection. In addition, the transfection ef-
ficiency of liposome-delivered genes was highly dependent upon the lipid composition,
lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used (141).
They can be prepared with defined physicochemical properties, such as size, shape and
surface charge, which in turn control the stability, distribution and uptake of DNA in
vivo.
Different ratios of DNA phosphate to polyethylenimine amine were used for encap-
sulation and delivery to liver cells of chloramphenicol acetyl transferase (CAT) or luci-
ferase expression plasmids in cationic, neutral and anionic liposomes with the galato-
cerebroside amount fraction of 8% for targeting on the hepatocyte asialoglycoprotein
receptor. All the liposome formulations demonstrated increased transfection efficiency
and significantly lower toxicity compared to nonencapsulated polyethylenimine com-
plexes. These formulations represent feasible systems for optimizing in vivo delivery
systems to hepatocytes (142). Moreover, liposomes composed of dipalmitoyl phospha-
tidylcholine, soybean-derived sterylglucoside mixture (SG) and Cho, showed greater ac-
cumulation in hepatocytes than in non-parenchymal cells after intravenous injection (143).
Kawaura and coworkers (144) studied the effect of monosialoganglioside containing
cationic liposomes with cationic Cho on the liposome mediated gene transfection into
mammalian culture cells. They found that both cationic liposomes with either a cationic
Cho derivative of a hydrophobic amino head group (I) or a hydrophilic amino head
13
P. Goyal et al.: Liposomal drug delivery systems – Clinical applications, Acta Pharm. 55 (2005) 1–25.
group (II) promoted the transfection of luciferase plasmids (pGL3) into HeLa and CHO-K1
cells more than the control cationic liposomes without monosialoganglioside. Further-
more, cationic liposomes with a cationic Cho derivative (II) were about ten times as ef-
fective as the commercially available cationic liposome lipofectin. Confocal fluorescence
microscopy showed that the liposome/DNA complex was transferred more efficiently
into the target cells by the monosialoganglioside-containing liposomes than by the lipo-
somes without monosialoganglioside (144).
Liposomes consisting of O,O’-ditetradecanoyl-N-(alpha-trimethyl ammonioacetyl)
diethanolamine chloride (DC-6-14) as a cationic lipid, phospholipid and Cho showed
effective gene transfection activity in cultured cells. DC-6-14 liposome-DNA complexes
were usually thought to have positive surface charge. However, depending on the ratio
of DNA to liposomes, zeta-potential of the complexes became negative. Surface charge
of these liposomes determine their biodistribution pattern, i.e., positively charged com-
plexes showed immediate lungs accumulation whereas negatively charged complexes
did not show such accumulation. Therefore, some surface modification of DC-6-14 lipo-
somes may improve the biodistribution and hence the targetability of their DNA com-
plexes (135). Transfer of interferon beta gene via cationic liposomes has been found to
induce regression of malignant glioma; this suggested the feasibility and safety of inter-
feron beta gene therapy, which may become an important treatment option for patients
with malignant glioma (137). Transfection efficiency of ultradeformable cationic liposo-
me/DNA complexes and their retention time within the organs by applying the formu-
lation onto hair-removed dorsal skin of mice was evaluated by Kim and coworkers (136).
The study demonstrated that genes were transported into several organs for six days
when applied once onto intact skin.
Recent advances have shown that it is possible to enhance the gene expression lev-
els of cationic liposomes. The main problem of cationic liposomes seems to be a lack of
organ or cell selectivity. Therefore, application of cell-specific targeting technology to
cationic liposomes would improve in vivo gene delivery and reduce unexpected side ef-
fects. Both liver parenchymal and non-parenchymal cells exclusively express large num-
bers of high-affinity asialoglycoprotein and mannose receptors, respectively. Receptor-
-mediated gene delivery systems are able to introduce foreign DNA into specific cell
types in vivo. However, not only the nature of the ligands grafted onto carriers but also
the overall physicochemical properties of the complexes need to be optimized for effec-
tive cell-selective targeting of plasmid DNA (145).
The transfection efficiency of transferrin conjugated cationic (Tf-DDAB) liposomes
was found to be much higher than that of unconjugated cationic liposomes. Target-ori-
ented Tf-dimethyl-dioctadecyl ammonium bromide (DDAB) liposomes were proven to
be very efficient in DNA delivery into the cervical cancer cells in culture (146). Gene
therapy of the brain is hindered by the presence of the blood-brain barrier (BBB). Shi
and Pardridge (147) reported the expression of an exogenous gene in the brain after
noninvasive intravenous administration of a 6- to 7-kb expression plasmid encoding ei-
ther luciferase or beta-galactosidase packaged in the interior of neutral pegylated im-
munoliposomes. Such liposomes are conjugated with the OX26 mAb (147) peptidomi-
metic mAb (148) to the rat transferrin receptor, which enables targeting of the plasmid
DNA on the brain via the endogenous BBB transferrin receptor. These studies indicate
that tissue-specific gene expression in the brain is possible after intravenous administra-
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tion of a nonviral vector with combined use of the gene targeting technology and tis-
sue-specific gene promoters (148). Unlike cationic liposomes, this neutral liposome for-
mulation is stable in blood and does not result in selective accumulation in the lungs.
Nabel et al. (150) studied Allovectin–7TM, a gene transfer liposomal product for the
treatment of metastatic melanoma, renal cell and colorectal carcinoma and demonstra-
ted that intralesional injection of Allovectin–7TM can be given safely and showed anti-
tumor activity in some patients. Yoshida et al. (137) studied the transfer of interferon
beta gene via cationic liposomes in patients with malignant glioma. They found that the
prepared liposomal formulation induced regression of experimental glioma. The study
indicated the feasibility and safety of interferon beta gene therapy, which may help treat
the patients with malignant glioma.
The clinical significance of hydroxyapatite (HAP) as a bone substitute has become
apparent in recent years and bone morphogenetic protein (BMP), a substance that in-
duces bone formation, has attracted much attention. Ono et al. (151) created a bone de-
fect on rabbit cranium and treated it with the BMP-2 gene (cDNA plasmid) combined
with cationic liposomes as a vector and confirmed the clinical usefulness of gene ther-
apy for bone formation. Antisense oligodeoxynucleotides (ODNs) possess a great poten-
tial as sequence-specific therapeutic agents. Sufficient concentration of intact ODN must
bypass membrane barriers and access the cytosol and nucleus for ODNs to be therapeu-
tically effective. Methew et al. (152) designed a liposome-based formulation that utilizes
listeriolysin O (LLO), the endosomolytic hemolysin from Listeria monocytogenes, to medi-
ate the escape of ODN from endocytic compartments into the cytosol. It was found that
ODN specific to murine intercellular adhesion molecule-1 (ICAM-1) encapsulated in
LLO-liposomes was released to the cytosol and trafficked to the nucleus, efficiently and
specifically suppressing the activation-induced expression of ICAM-1 at both protein
and mRNA levels. Delivery without LLO resulted in sequestration of ODN in vesicular
compartments leading to little inhibition of ICAM-1 expression, which supports the LLO
requirement of efficient cytosolic delivery using this system. It has been demonstrated
that LLO-mediated escape of ODN from intracellular vesicles is an effective approach to
achieve full therapeutic antisense activity in cultured macrophages.
Liposomes have been shown to potentiate DNA mediated vaccination. Intramuscular
immunization of mice with DNA encoding the S region of hepatitis B antigen entrapped
into cationic liposomes has led to improved humoral and cell mediated immunity, as
compared to the naked DNA or DNA complexed with preformed similar liposomes. It is
assumed that immunization with liposomes entrapped plasmid DNA involves antigen-
presenting cells (APC), either locally or in the regional draining lymph nodes (153).
CONCLUSIONS
Since the discovery of liposomes or lipid vesicles derived from self-forming enclo-
sed lipid bilayers upon hydration, liposome drug delivery systems have played a signif-
icant role in reformulation of potent drugs to improve their therapeutics. Thirty-four
years long research in liposomal drug delivery has led to vast improvement of the tech-
nology in terms of drug entrapment efficiency, vesicle stability in storage and in the
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body, design of vesicles for controlled release, site specific targeting and scale up pro-
duction. In parallel, noteworthy advances have been made in understanding and con-
trolling liposomal behavior in vivo. This has facilitated the application of a wide range of
liposomal drugs in the treatment and prevention of diseases in experimental animals
and clinically. Commercial introduction of the various liposomal formulations represents
a milestone in the history of liposomal drug delivery. Many more liposome-based drug
formulations can be expected in the near future both for delivery of conventional drugs
and for new biotechnology therapeutics such as recombinant proteins, antisense oligo-
nucleotides and cloned genes. With the recent development in the field, several compa-
nies are already actively engaged in expansion and evaluation of liposome products for
anticancer, antifungal therapy and for prophylaxis. The future of drug therapeutics may
not lie in the development of new chemical entities but in the modification of the exist-
ing drug molecules using suitable carriers to eliminate toxicity and improve activity, the
principalle of new lives for old drugs (149).
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Abbreviations, acronyms and codes. – ABCD – amphotericin B colloidal dispersion, ABLC – am-
photericin B lipid complex, ADR – adriamycin, AIDS – acquired immuno deficiency syndrome, AmB
– amphotericin B, APC – antigen-presenting cells, araC – cytosine-beta-D-arabinofuranoside, asODN
– antisense oligodeoxynucleotides, BBB – blood-brain barrier, BCH – cholesterol-carborane conjugate,
BMP – bone morphogenetic protein, BNCT – boron neutron capture therapy, BPD-MA – benzopor-
phyrin derivative monoacid ring A, CAB – conventional amphotericin B, CAT – chloramphenicol
acetyl transferase, Cho – cholesterol, DNA – deoxyribonucleic acid, DNR – daunorubicin, DOPE –
dioleoylphosphatidyl ethanolamine, DOTMA – dioleyloxypropyl trimethylammonium chloride,
DXR – doxorubicin, FR – folate receptor, HAP – hydroxyapatite, HIV – human immunodeficiency
virus, IgM – immunoglobulins M, ILP – pendant type immunoliposomes, L-ATRA – liposomal all-
trans-retinoic acid, LEM – liposome entrapped mitoxantrone, LLO – Listeriolysin O, MAC – Myco-
bacterium avium complex, MAE – mannobiose mono arachidic acid esters, MAI – Mycobacterium
avium intracellulare, MPEG – methoxypolyethylene glycol, MPS – mononuclear phagocyte system,
NB – neuroblastoma, ODNs – oligodeoxynucleotides, PDT – photodynamic therapy, PEG – poly-
ethyleneglycol, RES – reticuloendothelial systems, SG – sterylglucoside, SIL – stealth immunolipo-
somes, Tc – phase transition temperature, Tf-DDAB – transferrin conjugated dimethyl-dioctadecyl
ammonium bromide, TNF-alpha – tumor necrosis factor-alpha, VCR – vincristine.
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List of liposome products
Product name Drug Manufacturer (country)
Abelcet amphotericin B The Liposome Company (USA)
Allovectin-7TM HLA-B7 Plasmid Vical Incorporation (USA)
AmBisome amphotericin B NeXatar Pharmaceuticals (USA)
Amphocil amphotericin B SEQUUS Pharmaceuticals (USA)
Amphotec amphotericin B SEQUUS Pharmaceuticals (USA)
DaunoXomeTM Daunorubicin NeXatar Pharmaceuticals (USA)
DoxilTM Doxorubicin SEQUUS Pharmaceuticals (USA)
Doxosome Doxorubicin Indian Institute of Chemical Biology (India)
L-AMP-LRC-1 amphotericin B Seth G.S. Medical College and K.E.M. Hospital (India)
MiKasomeTM Amikacin NeXatar Pharmaceuticals (USA)
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S A @ E T A K
Liposomski sustavi za isporuku lijekova  Klini~ka primjena
PARVEEN GOYAL, KUMUD GOYAL, SENGODAN GURUSAMY VIJAYA KUMAR, AJIT SINGH, OM PRAKASH KATARE i
DINA NATH MISHRA
Od 1970. godine liposomi se intenzivno istra`uju kao nosa~i ljekovitih tvari za ispo-
ruku u odre|ene dijelova organizma. Unapre|enje i razvoj liposoma omogu}ili su nji-
hovu klini~ku primjenu u terapiji odre|enih bolesti. Na tr`i{tu je prisutan odre|en broj
ljekovitih oblika na bazi liposoma, a dio je jo{ u klini~kim pokusima. Svi su oni rezultat
boljeg razumjevanja raspodjele liposoma i interakcija izme|u lipida i ljekovite tvari. Mo-
gu}e je pripremiti liposome koji se mogu usmjeriti u odre|ena tkiva, stanice ili me|u-
stani~ne prostore, sa ili bez vezanih molekula za prepoznavanje na povr{ini membrane.
Ovaj revijalni ~lanak uglavnom obuhva}a liposome za terapiju karcinoma, bakterijskih i
gljivi~nih infekcija jer je u tim podru~jima primjena liposoma najvi{e opravdana i stoga
najvi{e istra`ivana. Osim toga, pravilnim izborom vektora za prijenos gena i na~ina is-
poruke mo`e se pove}ati i u~inkovitost prijenosa gena.
Klju~ne rije~i: liposomi, klini~ka primjena, terapija karcinoma, genska terapija, amfotericin B, dokso-
rubicin
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